M&A Deal Summary

Quotient Sciences Acquires Co-Formulate

On December 16, 2015, Quotient Sciences acquired life science company Co-Formulate

Acquisition Highlights
  • This is Quotient Sciences’ 1st transaction in the Life Science sector.
  • This is Quotient Sciences’ 1st transaction in the United Kingdom.

M&A Deal Summary

Date 2015-12-16
Target Co-Formulate
Sector Life Science
Buyer(s) Quotient Sciences
Deal Type Add-on Acquisition
Advisor(s) Realise Capital Partners (Financial)
Shakespeare Martineau (Legal)

Target

Co-Formulate

Nottingham, United Kingdom
Co-Formulate Ltd. is a contract product development company that provides a comprehensive range of formulation development, analytical and regulatory services to clients in the pharmaceutical, OTC consumer healthcare, personal care, nutritional supplements and veterinary industries.

Search 214,877 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Quotient Sciences

Nottingham, United Kingdom

Category Company
Founded 1990
Sector Life Science
DESCRIPTION

Quotient Sciences is a provider of outsourced, early-stage drug development services to the pharmaceutical industry. Quotient Sciences has brought innovation to the pharmaceutical services sector through its unique Translational Pharmaceutics® platform, which is proven to accelerate development timelines, reduce development costs, and drive improvement in R&D productivity. Quotient Sciences was founded in 1990 and is based in Nottingham, England.


DEAL STATS #
Overall 1 of 5
Sector: Life Science M&A 1 of 5
Type: Add-on Acquisition M&A Deals 1 of 4
Country: United Kingdom M&A 1 of 3
Year: 2015 M&A 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-06 SeaView Research

Miami, Florida, United States

SeaView Research, Inc. is a clinical research organization providing quality clinical pharmacology testing and laboratory services to the pharmaceutical industry.

Buy -